drugset / Trial / NCT04430361
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the efficacy and safety of megestrol acetate dispersible tablets combined with 5-HT3 receptor antagonist and dexamethasone triple antiemetic regimen and 5-HT3 receptor antagonist and dexamethasone combined antiemetic regimen in the control of CINV induced by hyperemetic chemotherapy.
Timeline
- Start
- 2018-09-07
- Primary completion
- 2020-12-30
- Completion
- 2021-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Megestrol Acetate | Other / unclassified | 160 mg | Oral |
| Background | Dexamethasone | Small molecule | 8 mg | Intravenous |